Tegoprazan‐Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Prospective, Randomized, Multicenter Study in Fujian, China
Helicobacter · 2024-11 · 29 (6)
DOI: 10.1111/hel.13151 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Helicobacter, online erschienen am 10.11.2024. Verfasst von Xueyan Lin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Amoxicillin, Helicobacter pylori, Drug Therapy, Combination. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Gastrointestinal Love-Baiqiuen Gastrointestinal Research Capacity Building Project Founds, Fujian Provincial Natural Science Foundation, Joint Funds for the Innovation of Science and Technology, Fujian Province.
Abstract (Originalsprache)
Introduction
Few studies have investigated the efficacy and safety of tegoprazan‐amoxicillin (TA) dual therapy for Helicobacter pylori eradication. We aim to evaluate the effectiveness and safety of different dosages of TA dual therapy for H. pylori eradication.
Methods
This prospective, randomized, open‐label, multicenter study was conducted at four centers in Fujian, China. H. pylori‐ infective patients were randomized 1:1:1 to receive one of the following treatments: bismuth quadruple therapy (BQT, esomeprazole 20 mg twice daily + potassium bismuth citrate 240 mg twice daily + amoxicillin 1 g twice daily + clarithromycin 500 mg twice daily), tegoprazan‐amoxicillin dual therapies (TA‐qd, tegoprazan 50 mg once daily + amoxicillin 1 g thrice daily; TA‐bid, tegoprazan 50 mg twice daily + amoxicillin 1 g thrice daily) for 14 days. The primary outcome was noninferiority in eradication rates of the different TA groups compared to the BQT group. Secondary outcomes encompassed an assessment of adverse reactions and clinical symptom relief. Additionally, exploratory outcomes were focused on the shifts in gut microbiota and a cost‐effectiveness analysis.
Results
A total of 321 patients were enrolled. The eradication rates in the BQT group, TA‐qd group, and TA‐bid group were 85.05% (91/107), 85.98% (92/107), and 85.98% (92/107) in the intention‐to‐treat analysis (ITT) (BQT vs. TA‐qd, 95% CI −8.50% to 10.36%, noninferiority p = 0.012; BQT vs. TA‐bid, 95% CI −8.50% to 10.36%, noninferiority p = 0.012); 91.00% (91/100), 91.09% (92/101), and 92.93% (92/99) in the modified intention‐to‐treat analysis (mITT) (BQT vs. TA‐qd, 95% CI −7.81% to 7.98%, noninferiority p = 0.006; BQT vs. TA‐bid, 95% CI −5.62% to 9.48%, noninferiority p < 0.001); 90.81% (89/98), 91.00% (91/100), and 93.81% (91/97) in the per‐protocol analysis (PP) (BQT vs. TA‐qd, 95% CI −7.83% to 8.19%, noninferiority p = 0.006; BQT vs. TA‐bid, 95% CI 4.46% to 10.46%, noninferiority p < 0.001). The incidence of adverse reactions in the TA‐qd and TA‐bid groups was significantly lower than in the BQT group (13.33%, 14.56%, and 27.18%, respectively; p = 0.017). The complete remissions of clinical symptoms for BQT, TA‐qd, and TA‐bid were 36.89%, 65.71%, and 68.93%, respectively, had significant differences ( p < 0.001). Two weeks of TA therapy altered gut microbiota diversity and composition, but that recovered 4 weeks after discontinuation. The cost‐effectiveness ratios (CERs) for BQT, TA‐qd, and TA‐bid were 1.85 CNY, 2.08 CNY, and 3.69 CNY, respectively.
Conclusion
Both TA dual therapies provided satisfactory eradication rates of > 90% for eradicating H. pylori , fewer adverse reactions, and greater clinical symptom relief compared to BQT, with a mild, reversible impact on gut microbiota. In addition, the TA dual therapy with low doses of tegoprazan showed better cost‐effectiveness. Trial Registration Chinese Clinical Trial Register and registration No.: ChiCTR2300071997
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China.
- Department of Gastroenterology, Fujian Provincial Hospital, Fuzhou, China.
- Department of Gastroenterology, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.
- Department of Gastroenterology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
- Department of Gastroenterology, Fujian Provincial Geriatric Hospital, Fuzhou, China.
- Department of Gastroenterology, Pingtan Comprehensive Experimental Area Hospital, Fuzhou, China.
ORCID-Profile: Xueyan Lin, Zhihui Lin
Förderung
- Gastrointestinal Love-Baiqiuen Gastrointestinal Research Capacity Building Project Founds
- Fujian Provincial Natural Science Foundation
- Joint Funds for the Innovation of Science and Technology, Fujian Province
- Natural Science Foundation of Fujian Province
Zitieren
APA
Lin, X., Huang, H., Liu, Y., Zeng, Y., Lu, S., Xu, X., Lin, Y., Qiu, F., Cai, F., Pan, J., Huang, S., Lin, S., Lin, A., Lin, Z., & Huang, X. (2024). Tegoprazan‐Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Prospective, Randomized, Multicenter Study in Fujian, China. Helicobacter, 29(6). https://doi.org/10.1111/hel.13151
Vancouver
Lin X, Huang H, Liu Y, Zeng Y, Lu S, Xu X, et al. Tegoprazan‐Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Prospective, Randomized, Multicenter Study in Fujian, China. Helicobacter. 2024;29(6). doi:10.1111/hel.13151
BibTeX
@article{Lin2024,
author = {Lin, Xueyan and Huang, Huping and Liu, Yijuan and Zeng, Yanling and Lu, Shiyun and Xu, Xuefeng and Lin, Yun and Qiu, Feng and Cai, Fangfang and Pan, Jie and Huang, Shaozhong and Lin, Shaowei and Lin, Aiping and Lin, Zhihui and Huang, Xueping},
title = {Tegoprazan‐Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Prospective, Randomized, Multicenter Study in Fujian, China},
journal = {Helicobacter},
year = {2024},
volume = {29},
number = {6},
doi = {10.1111/hel.13151}
}
EUVIMED